Characterisation of the T-cell response to Ebola virus glycoprotein amongst survivors of the 2013–16 West Africa epidemic

T. R. W. Tipton (), Y. Hall, J. A. Bore, A. White, L. S. Sibley, C. Sarfas, Y. Yuki, M. Martin, S. Longet, J. Mellors, K. Ewer, S. Günther, M. Carrington, M. K. Kondé and M. W. Carroll
Additional contact information
T. R. W. Tipton: Public Health England
Y. Hall: Public Health England
J. A. Bore: Center for Training and Research on Priority Diseases including Malaria in Guinea (CEFORPAG)
A. White: Public Health England
L. S. Sibley: Public Health England
C. Sarfas: Public Health England
Y. Yuki: Frederick National Laboratory for Cancer Research in the Laboratory of Integrative Cancer Immunology, National Cancer Institute
M. Martin: Frederick National Laboratory for Cancer Research in the Laboratory of Integrative Cancer Immunology, National Cancer Institute
S. Longet: Public Health England
J. Mellors: Public Health England
K. Ewer: The Jenner Institute
S. Günther: Bernhard Nocht Institute for Tropical Medicine
M. Carrington: Frederick National Laboratory for Cancer Research in the Laboratory of Integrative Cancer Immunology, National Cancer Institute
M. K. Kondé: Center for Training and Research on Priority Diseases including Malaria in Guinea (CEFORPAG)
M. W. Carroll: Public Health England

Nature Communications, 2021, vol. 12, issue 1, 1-9

Abstract: Abstract Zaire ebolavirus (EBOV) is a highly pathogenic filovirus which can result in Ebola virus disease (EVD); a serious medical condition that presents as flu like symptoms but then often leads to more serious or fatal outcomes. The 2013–16 West Africa epidemic saw an unparalleled number of cases. Here we show characterisation and identification of T cell epitopes in surviving patients from Guinea to the EBOV glycoprotein. We perform interferon gamma (IFNγ) ELISpot using a glycoprotein peptide library to identify T cell epitopes and determine the CD4+ or CD8+ T cell component response. Additionally, we generate data on the T cell phenotype and measure polyfunctional cytokine secretion by these antigen specific cells. We show candidate peptides able to elicit a T cell response in EBOV survivors and provide inferred human leukocyte antigen (HLA) allele restriction. This data informs on the long-term T cell response to Ebola virus disease and highlights potentially important immunodominant peptides.

Date: 2021
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-021-21411-0 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:12:y:2021:i:1:d:10.1038_s41467-021-21411-0

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-021-21411-0

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().